SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indevus Pharmaceuticals (NasdaqNM:IDEV)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sidney Street who wrote (21)8/2/2004 2:09:31 PM
From: rkrw   of 78
 
Per the Madaus deal (sanctura licensor) Idev will owe Madaus 25% of the royalty. I'm guessing 20% royalty, 15% net, after Madaus.

Miljenko gave me a pointer to this awhile ago:

sec.gov

ii) that in the event that Interneuron enters into a
sublicense in the Territory to a Third Party or Third
Parties, in lieu of royalty payments set forth in SECTION
5.2.1, Interneuron shall pay Madaus twenty-five percent
(25%) of sublicensing royalty on net sales of Licensed
Product(s) that Interneuron receives in respect of such
sublicense(s), provided, however, that during the first
five years of the Distribution Period, in no event shall
such sublicense royalty payments to Madaus be less than
four percent (4%) of the net sales of Licensed Product(s)
by a sublicensee or sublicensees in the sublicensed
territory; and
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News